Metropolitan Veterinary Hospital - Akron
Specialty hospital / research center
4 current cancer treatment or research opportunities
About Metropolitan Veterinary Hospital - Akron
Metropolitan Veterinary Hospital - Akron is the participating hospital named in the current study listing below. The hospital is part of the Ethos Veterinary Health network, while Ethos Discovery coordinates the research program. Screening, enrollment and required visits are handled by the participating hospital; owners should confirm that the location is still enrolling before making travel plans.
Metropolitan Veterinary Hospital - Akron official website →
Who the current listings are forDogs
Cancer types currently listedHemangiosarcoma, Lymphoma, Oral Melanoma, Osteosarcoma
Where visits take placeMetropolitan Veterinary Hospital, 734 Alpha Dr, Highland Heights, OH 44143
Metropolitan Veterinary Hospital, 1053 S Cleveland-Massillon Rd, Akron, OH 44321
Current options at Metropolitan Veterinary Hospital - Akron
Open an option to see who may qualify, locations, costs or coverage, contact details and the official source.
Gilvetmab treatment study for canine malignant melanoma
Ethos Veterinary Health · USA
Now enrolling patients
What is being offered: Safety and efficacy study of gilvetmab in dogs with malignant melanoma; age ≥1 year.
Who may qualify: Confirmed cancer diagnosis required; Min weight lb: 6.6; Active tumor required; Min age years: 1
Costs / coverage: 🟢 Fully funded. All study-related visits are covered at no cost to the pet owner.
Contact: Contact participating Ethos hospital through official study page.
Location
- Metropolitan Veterinary Hospital, 734 Alpha Dr, Highland Heights, OH 44143
Official study / enrollment information →
Novel vaccine versus carboplatin after amputation for canine appendicular osteosarcoma
Ethos Veterinary Health · USA
Now enrolling patients
What is being offered: Appendicular OSA; age >=1 year, >=44 lb, otherwise in good general health; cytologic/histologic confirmation. Current Ethos owner page lists 9 enrolling hospitals. An older AVMA registry listing contains additional historical sites; those are not promoted without current site-level confirmation.
Who may qualify: Confirmed cancer diagnosis required; Min weight lb: 44; Active tumor required; Appendicular location; Min age years: 1; Planned amputation
Costs / coverage: 🟡 Partially funded. All study-related visits are covered, including up to $4,000 toward amputation.
Contact: Contact participating Ethos hospital through official study page.
Participating locations
- Metropolitan Veterinary Hospital, 734 Alpha Dr, Highland Heights, OH 44143
- Metropolitan Veterinary Hospital, 1053 S Cleveland-Massillon Rd, Akron, OH 44321
Official study / enrollment information →
SOLID-Relapse — treatment study for dogs with relapsed multicentric nodal lymphoma
Colorado Animal Specialty & Emergency (CASE) / Ethos Discovery · USA
Currently enrolling
What is being offered: Randomized lymphoma treatment under an Ethos oncologist plus genomic/biomarker sampling
Who may qualify: Confirmed cancer diagnosis required; Prior chemo; Active tumor required; Lymphoma response: First relapse after remission; More than one relapse; Planned chemo
Costs / coverage: 🟡 Partially funded. Study provides screening and scheduled laboratory testing plus up to $4,500 toward chemotherapy, exams, diagnostics and medications for chemotherapy-related side effects.
Contact: CASE Clinical Trials — CASEtrials@ethosvet.com; 303-545-2273
Location
- Metropolitan Veterinary Hospital, 1053 S Cleveland-Massillon Rd, Akron, OH 44321
Official study / enrollment information →
Ethos-PUSH precision-medicine umbrella study for splenic hemangiosarcoma
Ethos Discovery / multicenter specialty hospitals · USA
Open / currently enrolling
What is being offered: Phase 1 splenectomy/hemoabdomen study; dogs confirmed with non-metastatic splenic HSA can continue to fully funded active-treatment Phase 2, with treatment assigned among doxorubicin, doxorubicin+rapamycin, doxorubicin+sorafenib, or oral paclitaxel regimens.
Who may qualify: No metastasis; Active tumor required; Splenic primary; Planned surgery; Pre splenectomy; Min weight kg exclusive: 5; Max weight kg exclusive: 45
Costs / coverage: 🟡 Partially funded overall. Phase 1 provides $1,000 toward splenectomy; owners remain responsible for other initial surgical/screening costs. Dogs subsequently confirmed with splenic HSA and no metastases can enter fully funded Phase 2 (> $10,000 value). Sponsor states up to $3,000 for study-related side effects.
Contact: Ethos Discovery enrollment form / participating hospital; CASE: 303-545-2273
Location
- Metropolitan Veterinary Hospital, 1053 S Cleveland-Massillon Rd, Akron, OH 44321
Official study / enrollment information →
Before you contact the center
A listing here does not mean every pet will qualify. Enrollment can change, and the study team makes the final decision after reviewing your pet’s diagnosis, records and previous treatment.
Have the pathology report, recent imaging and treatment history ready. Ask whether a referral is required, which visits must happen in person and what the study pays for before making travel plans.
Check all options for your pet →
Free to use. No registration or paid report.
